Acute myeloid leukemia and myelodysplatic syndrome: parenteral-, enteral- and only oral nutrition during remission induction treatment
Recruiting
- Conditions
- Acute myeloid leukemia and late stage myelodysplastic syndrome
- Registration Number
- NL-OMON20839
- Lead Sponsor
- Maxima MC
- Brief Summary
Not available
- Detailed Description
Not available
Recruitment & Eligibility
- Status
- Recruiting
- Sex
- Not specified
- Target Recruitment
- 180
Inclusion Criteria
Adult patients (= 18 years), newly diagnosed with AML or MDS who will start with intensive remission induction chemotherapy
Exclusion Criteria
•Patients with cognitive disorders or severe emotional instability
•Patients who are unable to speak, understand or read the Dutch language.
Study & Design
- Study Type
- Observational non invasive
- Study Design
- Not specified
- Primary Outcome Measures
Name Time Method Body composition (fat mass (index), fat-free mass (index), muscle mass and body fat distribution).
- Secondary Outcome Measures
Name Time Method Health related quality of life, functional capacity, muscle strength, tolerance of PN, EN and only oral nutrition (i.e. (severity of) nutrition impact symptoms, laboratory serum liver value tests, central venous catheter infections), nutritional status and course of treatment (chemotherapy-induced toxicity, complications, serum liver test abnormalities, duration of hospital stay, treatment-related mortality, progression-free survival, overall survival ). Furthermore, patient-, disease- and treatment- characteristics, and data about nutritional intake will be collected.